<DOC>
	<DOCNO>NCT00250094</DOCNO>
	<brief_summary>1.1 To determine regulation topoisomerase I II follow alternate prolonged exposure topotecan etoposide ( VP-16 ) 1.2 To determine time progression objective response rate treatment patient incurable ovarian cancer .</brief_summary>
	<brief_title>Clinical Benefit Topoisomerase Downregulation</brief_title>
	<detailed_description>The rationale study downregulation topoisomerase enzyme ovarian cancer relationship cell cycle distribution cancer cell prolong continuous exposure topo I II poison well understand relationship cell cycle topo poisoning , may lead good clinical trial design .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>All patient , 18 year age old , incurable ovarian advance cancer eligible provide measurable disease CTscan imaging , evaluable disease tumor marker , follow criterion describe Rustin et al . ( 14 ) . ( Response specific treatment occur two CA125 sample 50 % decrease , confirm fourth sample ( 50 % response ) , serial decrease three sample great 75 % ( 75 % response ) . The final sample least 28 day previous sample . ) Patients must life expectancy least 12 week . Patients must Zubrod performance status 02 . Patients must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 cells/mm3 platelet count &gt; 100,000/mm3 absence regular red blood cell transfusion requirement . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . Patients symptomatic brain metastasis exclude study . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Ovary</keyword>
	<keyword>Cancer</keyword>
</DOC>